Onconova Therapeutics (ONTX) Insiders Make Significant Share purchases

Monday, February 12, 2018 10:15 PM ET

Onconova Therapeutics (ONTX) Insiders Make Significant Share purchases

Three insiders — James J Marino, Director, Tyndall Capital Partners Lp, 10% Owner, and 683 Capital Management, LLC, 10% Owner — purchased 1,350,000 shares of Onconova Therapeutics having a market value of approximately $1,318,120 today, as disclosed in form 4 documents filed with the SEC. This is the first insider buy/sell trade in the past 90 days.

Compared to its peers over the last 90 days, insider buy/sell trading at Onconova Therapeutics is higher than the 45-company peer group average. Biopharmaceuticals peer group saw 40 buy/sell trades during this period for an average of 0.9 transactions per company. The number of shares per buy/sell trade for Onconova Therapeutics insiders was also higher. Within the peer group there were 414,767 shares purchased and 1,033,608 shares sold with company insiders disposing of 15,471 shares on average.

For the purpose of evaluating significant insider buying and selling all trades reported to the SEC that involve awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers have been eliminated in data obtained to evaluate and write this story.

Today’s Insider Activity
* James J Marino, Director, bought 50,000 shares
* Tyndall Capital Partners Lp, 10% Owner, bought 1,100,000 shares
* 683 Capital Management, LLC, 10% Owner, bought 200,000 shares

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at info@uptickdata.com. Copyright 2018 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.